Product Development Update

Syntopix Group plc
01 August 2006


For immediate release                                              1 August 2006

                                        
                                        
                               SYNTOPIX GROUP PLC

                         ('Syntopix' or 'the Company')



FIRST PRODUCTS PROGRESS INTO DEVELOPMENT


Syntopix Group plc (AIM: SYN), the drug discovery and development company
focused on dermatological diseases, is delighted to announce that three
candidates from its research pipeline, for which patent applications have been
made, will be taken forward into clinical product development for the treatment
of acne and staphylococcal infections.


In accordance with the Company's plans and as outlined in the Company's
admission document, SYN-24-0017 will become the first candidate to enter
pre-clinical development as a topical remedy for the prevention and treatment of
skin infections due to Staphylococcus aureus.


In parallel, a synergistic combination of SYN-24-0017 with a metal salt will be
developed as a topical treatment for acne vulgaris. An additional remedy for
acne will also be developed from a synergistic combination of SYN-24-0401 with
SYN-24-0403 or its salt.


The compounds all have a history of use in man in line with the Company's
reduced risk business model. SYN-24-0017 is an anti-oxidant present in a wide
variety of food and cosmetic products. SYN-24-0401 is an antifungal ingredient
in personal care products. Compounds related to SYN-24-0403 are present in some
combination products for the treatment of secondarily infected atopic
dermatitis. SYN-24-0017 and SYN-24-0401 are effective antimicrobials when used
alone, but Syntopix has shown that their activity can be enhanced when used in
combination with certain metal salts or with SYN-24-0403 respectively.


Commenting on this important milestone, CEO Rod Adams said: 'We are extremely
pleased to have made significant scientific advancements since the flotation of
Syntopix in March this year. We have selected three lead candidates from our
portfolio to enter formulation and clinical studies in line with expectations
and I am very excited about the quality of our development programme.'



For further information please contact:

Syntopix Group plc                                            0845 125 9204

Gwyn Humphreys, Chairman
Rod Adams, Chief Executive Officer
www.syntopix.com

KBC Peel Hunt Ltd                                             020 7418 8900

Megan MacIntyre

Buchanan Communications                                       020 7466 5000

Mark Court, Tim Anderson, Mary-Jane Johnson



About Syntopix Group plc

Syntopix Group plc began as a spin-out company from the University of Leeds. The
Syntopix strategy is designed to reduce the risks and costs of drug development
by avoiding the use of new chemical entities. Flotation on AiM in March 2006
enabled the Company to take its first candidate products into the development
pipeline. The Company's therapeutic focus is currently on acne and
staphylococcal skin infections. Syntopix has a collaborative approach and will
work with partners in the pharmaceutical and healthcare sector to expedite a
rapid route to market.








                      This information is provided by RNS
            The company news service from the London Stock Exchange